In this edition of In the News, learn about digital medicine and what it means for children with autism spectrum disorder and co-occurring attention deficit/hyperactivity disorder (ADHD). Read about a variation in care study, a recent FDA approved drug treatment for a specific childhood cancer, and why two Children’s Hospital of Philadelphia researchers are calling for improved pediatric palliative care measures. And lastly, join us in celebrating the addition of six new initiatives to CHOP’s Frontier Programs.
Tag Archive: Children’s Hospital of Philadelphia
Creating the opportunity for every child with cancer to enjoy a healthy life beyond their cancer experience is the dream for pediatric oncology researchers. New grants awarded by the National Cancer Institute Moonshot Initiative through a multi-institutional, collaborative group — the Pediatric Immunotherapy Discovery and Development Network (PI-DDN) — aim to bring this dream closer to reality by fundamentally changing our understanding of how to harness the power of the immune system to treat childhood cancers.
One-month-old Connor only dimly perceives the world around him. Just two months later, when he sees his mother’s beaming face or hears his father’s hearty laugh, he smiles with recognition. And by the time Connor reaches his first birthday, he’s starting to put one foot in front of the other and verbally communicate with his parents. Just what accounts for these significant changes?
Leading the charge to develop new, targeted approaches to treat disease, Children’s Hospital of Philadelphia Research Institute investigators have uncovered more of the mechanistic underpinnings of the migratory T cell response, and CHOP announced the inaugural Patricia Brophy Endowed Chair in Neuroblastoma Research to advance innovation into less toxic treatment options for specific cancers. Out in the community, CHOP has teamed up with the Philadelphia Housing Development Corporation for the pilot program of its Healthier Together initiative, and researchers are learning how best to help survivors of violence after they are discharged from the hospital.
Thrombosis — the abnormal, life-threatening blood clots that form in the artery or vein — does not discriminate. Young. Old. Rich. Poor. Gender. Race. Ethnicity. We’re all in this together. We’re all susceptible. Some more so than others.
Up to 900,000 people in the U.S. are affected by blood clots each year; 100,000 will die, which is greater than the total number of people who lose their lives each year to AIDS, breast cancer, and motor vehicle crashes combined.
The voice of Kai Tan, PhD, rises and quickens when he considers the potential of single cell technology to zero in on pathogenesis of cancer and other diseases. He points to the attention this course of research is receiving via funding from organizations such as the National Cancer Institute (NCI) Moonshot Initiative and the Chan Zuckerberg Initiative’s Human Cell Atlas project. In fact, Dr. Tan is himself is a valued contributor to the single cell revolution, and his work will continue with a recent NCI grant for the development of a pediatric tumor cell atlas.
The Fifth Annual Microbiome Symposium: Microbes, Metabolomics, and Modern Diseases highlighted the synergy of the Children’s Hospital of Philadelphia and University of Pennsylvania scientific community to produce incredibly novel and exciting research.
Hosted by the PennCHOP Microbiome Program, the Nov. 8 symposium brought experts from the fields of microbiology, immunology, gastroenterology, cell and molecular physiology, and pathology together with a common goal: to share developments from their labs with the end game of improving outcomes for individuals with chronic disease.
Larry Jameson, MD, PhD, executive vice president, University of Pennsylvania Hospital System and dean of the Perelman School of Medicine, welcomed attendees to the packed Gaulton Auditorium.